NCT03045406 2025-06-24
CARAVAGGIO
Fadoi Foundation, Italy
Phase 3 Completed
Clinical Trials
9 trialsNCT03080883 2025-05-18
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Academic and Community Cancer Research United
Phase 3 Completed
NCT02744092 2023-10-03
CANVAS
Alliance Foundation Trials, LLC.
Phase NA Completed
NCT01999179 2022-05-18
Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis
Medical College of Wisconsin
Phase NA Completed
NCT02369653 2022-03-08
A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
Bristol-Myers Squibb
Phase 3 Completed
NCT02585713 2020-08-04
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
Academic and Community Cancer Research United
Phase 3 Completed
NCT02366871 2020-03-31
Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy
University of Colorado, Denver
Phase 2 Completed
NCT02958969 2019-12-17
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
Dana-Farber Cancer Institute
Phase 4 Completed
NCT00320255 2016-08-16
A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer
Bristol-Myers Squibb
Phase 2 Completed